Cordant’s Comprehensive Mental Health Adherence Testing Identifies What Is Not Seen Today
The challenges to mental health care posed by the coronavirus pandemic are vast. In addition to significantly increased reports of anxiety and depression and a sharp decrease in needed medical care, clinicians are seeing worsening mental health outcomes, increased substance use, and elevated suicidal ideation.¹
According to a recent survey, 41% of adults reported symptoms of anxiety and/or depressive disorder in January 2021 (a significant increase from the 11% reported during the same period in 2019) and 36% reported delaying or not getting the medical care they need because of the pandemic.² Additionally, 13% of adults reported new or increased substance use due to coronavirus-related stress, and 11% reported thoughts of suicide in the past 30 days.¹
Cordant offers an extensive drug testing menu with more than 180 metabolites and parent drugs, with more than 60 mental health testing options in oral fluid.
Integrated Results Management Reports
Laboratory results management reports allow you to easily monitor your testing protocols, testing frequency and positivity trends to help you offer better care for your patients.
Watch this video to learn more about Cordant’s findings in our short video, Unlocking the Data: Cordant’s Mental Health Adherence Testing Identifies What Is Not Seen Today.
What are you missing?
An analysis of drug test results from mental health patients in Cordant’s program where medications were reported as prescribed revealed surprising insights:
Demonstrated inconsistent results
0%
Tested negative for prescribed medications
0%
Tested positive for illicit drugs
0%
Tested positive for non-prescribed medications
0%
Analysis of 17,720 samples from mental health patients in Cordant’s program where a medication was reported as prescribed with the test order; Jan 2018–Sept 2019
Medication non-adherence accounts for 30–50% of treatment failures.
Studies show that patients often overstate adherence because they fear disappointing their provider and that clinicians generally overestimate their own ability to identify and quantify non-adherence among their patients. This highlights the importance of objective and validated approaches to measurement, such as testing.
Non-adherence to antipsychotic medications averages 42%
Non-adherence to antidepressant medications averages 34%
Non-adherence to medication represents a major problem that limits the effectiveness of treatment and adds to the burden of illness and cost of health care.
Drug testing is an effective technology when the right test is selected for the right person at the right time.
Medication adherence should be periodically monitored by laboratory testing.
Results should be used to guide patient care, modify treatment plans and confirm clinical impressions.
Based on risk assessment, match provider interventions with medication regimens to patient’s individual needs.
Previous
Next
Please complete this form to request more information.